We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Oncology

Journal Scan / Research · June 11, 2020

Trifluridine/Tipiracil Plus Bevacizumab in Patients With Untreated Metastatic Colorectal Cancer Ineligible for Intensive Therapy

Annals of Oncology

 

Additional Info

Annals of Oncology
Trifluridine/Tipiracil Plus Bevacizumab in Patients With Untreated Metastatic Colorectal Cancer Ineligible for Intensive Therapy: The Randomized TASCO1 Study
Ann. Oncol 2020 Jun 01;[EPub Ahead of Print], E Van Cutsem, I Danielewicz, MP Saunders, P Pfeiffer, G Argilés, C Borg, R Glynne-Jones, CJA Punt, AJ Van de Wouw, M Fedyanin, D Stroyakovskiy, H Kroening, P Garcia-Alfonso, H Wasan, A Falcone, A Kanehisa, A Egorov, P Aubel, N Amellal, V Moiseenko

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading